A new technology may be released soon that goes further to protect patients with renal failure while undergoing an MRI. Luna nanoWorks and the Washington University School of Medicine co-authored a paper that was published in the Journal of Medicinal Chemistry. The paper introduces a new avenue of gadolinium delivery that could protect patients with insufficient kidney elimination from the debilitating and sometimes deadly disease Nephrogenic Systemic Fibrosis after undergoing and MRI. The paper describes the new contrast agent as encapsulating the gadolinium metal within an extremely stable carbon nanosphere, thus allowing for extended existence in the body. Patients with kidney insufficiency eliminate toxins slower than those with normal renal function. Luna's HYDROCHALARONE™ molecules have initially proven to be more effective at enhancing images and are potentially safer than current gadolinium-containing contrast agents, which have been associated with Nephrogenic Systemic Fibrosis. Currently gadolinium contrast agents are formulated in a chelate to prevent toxicity, but the chelate agent is designed to be in the body for a short period of time. In those with renal failure their slow elimination process allows the gadolinium to separate from the chelate, thus exposing the patient to the toxic metal. The new delivery process of gadolinium may be a boon to those who need to undergo and MRI, but suffer from kidney failure. The U.S. Food and Drug Administration continues to review reports of patients who have developed NSF after receiving the chelate-based gadolinium agent. In response to reports of patient exposure, the FDA issued a black-box warning, the highest available, to warn the medical community of the possible consequences of using the chelate-based gadolinium in patients with renal insufficiency.